This article is more than 5 years old. Information may no longer be current.

Subconjunctival anti-VEGF injection reduces corneal neovascularization

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PARIS — Subconjunctival injection of bevacizumab seems to be effective in reducing corneal neovascularization, according to a study carried out in Rouen, France.

"A single dose of 0.1 mL bevacizumab (25 mg/mL) was injected under the conjunctiva, as near as possible to the site of neovascularization, under local anesthesia, in 13 eyes of 12 patients. The patients received between two and four injections over a period of 4 months," Julie Gueudry, MD, said at the meeting of the French Society of Ophthalmology.

However, visual acuity did not significantly improve, and three cases of corneal epithelial ulcers were reported.

"Corneal ulceration is an adverse effect that we must consider," Dr. Gueudry said.

No alteration of IOP and no systemic side effects were observed.

Less invasive and more comfortable means of administering anti-VEGF agents to the eye, such as topical eye drops, are currently under investigation and might be an alternative in the future.